- Home
- CRVS vs EBS Comparison
CRVS vs EBS Comparison
Compare CRVS & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- EBS
- Stock Information
- Founded
- CRVS 2014
- EBS 1998
- Country
- CRVS United States
- EBS United States
- Employees
- CRVS N/A
- EBS N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- EBS Biotechnology: Pharmaceutical Preparations
- Sector
- CRVS Health Care
- EBS Health Care
- Exchange
- CRVS Nasdaq
- EBS Nasdaq
- Market Cap
- CRVS 305.4M
- EBS 353.9M
- IPO Year
- CRVS 2016
- EBS 2006
- Fundamental
- Price
- CRVS $4.11
- EBS $7.30
- Analyst Decision
- CRVS Strong Buy
- EBS Strong Buy
- Analyst Count
- CRVS 4
- EBS 3
- Target Price
- CRVS $15.00
- EBS $14.33
- AVG Volume (30 Days)
- CRVS 1.2M
- EBS 1.4M
- Earning Date
- CRVS 08-05-2025
- EBS 08-05-2025
- Dividend Yield
- CRVS N/A
- EBS N/A
- EPS Growth
- CRVS N/A
- EBS N/A
- EPS
- CRVS N/A
- EBS N/A
- Revenue
- CRVS N/A
- EBS $965,400,000.00
- Revenue This Year
- CRVS N/A
- EBS N/A
- Revenue Next Year
- CRVS N/A
- EBS $18.88
- P/E Ratio
- CRVS N/A
- EBS N/A
- Revenue Growth
- CRVS N/A
- EBS N/A
- 52 Week Low
- CRVS $1.78
- EBS $4.02
- 52 Week High
- CRVS $10.00
- EBS $15.10
- Technical
- Relative Strength Index (RSI)
- CRVS 53.94
- EBS 62.33
- Support Level
- CRVS $3.79
- EBS $6.59
- Resistance Level
- CRVS $4.31
- EBS $7.29
- Average True Range (ATR)
- CRVS 0.29
- EBS 0.39
- MACD
- CRVS 0.00
- EBS 0.05
- Stochastic Oscillator
- CRVS 72.64
- EBS 92.89
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.